FDA

Our in-brief roundup of notable healthcare and life sciences stories from the last two weeks.

New FDA-SEC information-sharing framework heightens scrutiny of disclosures, insider trading risks and prediction market activity.

FDA issues a request for information to gather feedback on challenges, scientific needs, and regulatory approaches for advancing botanical drug products.

The agencies signed a MOU to support the sharing of nonpublic information about regulated products and possible violations of law.

AI health companies want national licensing system amid debate how liability works when autonomous clinical AI is involved.

Our in-brief roundup of notable stories from the last week.

Our in-brief roundup of notable healthcare and life sciences stories from the last two weeks.

Unapproved obesity drug retatrutide is fueling a fast-growing black market of counterfeit products, exposing gaps in the regulatory system as federal agencies struggle to keep up.